Prognica Research Fellows Program 2026 Cohort: Closed Round Archive
The Prognica Research Fellows Program 2026 cohort is closed. This historical reference records its published terms; Prognica has not announced dates for the next cohort.
Prognica Research Fellows Program 2026 Cohort: Closed Round Archive
The Prognica Research Fellows Program’s inaugural Class of 2026 is closed to new applications. Prognica Labs’ official application page says submissions ended on 30 August 2026, the portal no longer accepts applications, and late or incomplete submissions are not carried forward. The program page says dates for the next cohort will be announced there; it does not provide a successor deadline. This entry preserves the terms and process published for the completed round so applicants can understand what the opportunity offered and prepare to check for a future announcement. It is not an open call.
The application page still contains a “Review under way” status line even though it says applicants would hear by 26 September 2026, a date that has passed. Prognica’s separate cohort directory now presents 15 researchers as the 2026 Fellows, while the application page describes selection of ten Fellows for the inaugural cohort. Because these official pages do not reconcile that difference, this archive records the discrepancy rather than treating either number as a corrected final selection count. The directory indicates that a cohort is being presented, but it does not announce a new application window.
At a glance
| Detail | Published terms for the 2026 cohort |
|---|---|
| Program | Prognica Research Fellows Program, inaugural Class of 2026 |
| Provider | Prognica Labs |
| Status | Applications closed; the official page says next-cohort dates will be announced later |
| Published deadline | 30 August 2026; the portal says it stopped accepting submissions and late or incomplete applications do not carry forward |
| Fellowship term | Six months; the program timeline listed a start on 1 October 2026 and close on 31 March 2027 |
| Cohort size | Application page says ten Fellows; official cohort directory displays 15 researchers |
| Published value | Estimated $12,000 per Fellow; up to $20,000 for Fellows awarded laboratory validation |
| Cost to selected Fellows | Complimentary; no application or participation fee |
| Format | Global and remote; Prognica’s team conducts any awarded laboratory work |
| Official pages | Program overview · Closed application page · Cohort directory |
The date retained in the page metadata is the actual closing date for the 2026 call. Its historical-reference status distinguishes that closed deadline from a live opportunity deadline. Anyone finding this page later should use Prognica’s program page to check whether a new cohort has been announced and read that cohort’s terms afresh; prior-cycle figures are not a promise that a future round will have the same benefits, cohort size or requirements.
What the 2026 fellowship offered
Prognica described a six-month fellowship built around connecting computational work to an interpretable research result. Selected Fellows were to receive complimentary, priority access to Prognica’s platform for the length of the program. The published description named Autonomous Asset Discovery, the In-Silico Evaluation Suite, Market and Commercial Insight, Clinical Operations and Business Development. It said all modules were unlocked and no usage caps applied during the fellowship term. The platform access was a program benefit, not a cash payment to the Fellow.
The listed support also included guided onboarding, data-migration assistance and a project-specific setup plan. Training topics named by Prognica included virtual-screening design, molecular dynamics and free-energy calculations, ADMET and liability prediction, multi-omics integration and clinical variant interpretation. Training materials and recordings were part of the described offer. The aim was to help researchers use the tools in the context of a defined project rather than simply provide an account without guidance.
Methodology support was presented as another core benefit. The official description referred to study design, power and sample size, quality control, applicability domains, negative controls and analysis planning. Fellows were also offered priority technical support, priority consideration for feature requests, publication and methods assistance, a community of Fellows, a certificate and a digital recognition badge. Prognica said Fellows could have opportunities for co-authored publications, case studies and later collaborations; these are described as opportunities, not guaranteed publications or employment.
The published estimated value was $12,000 per Fellow. Prognica described the fellowship as provided at no cost to those selected and did not describe the $12,000 as a stipend or unrestricted grant. The figure should therefore be understood as the estimated value of access and support, not money available for living costs or personal expenses.
Up to three Fellows could receive additional wet-laboratory validation support. Prognica gave an indicative value of $8,000 for each award, which could raise the estimated combined value to $20,000. Example activities included target validation, PCR or qPCR assay development, protein expression and cell-based readouts. The program said the work would be scoped with the Fellow and run by its translational biology team. The validation award was optional: applicants without a validation plan could still be assessed for the fellowship and were not disadvantaged for omitting that award request.
Eligibility published for the closed round
The 2026 call welcomed applicants working, or seeking to work, in drug discovery, multi-omics, molecular diagnostics and translational biology. The eligible career groups listed by Prognica were PhD candidates, postdoctoral researchers, clinical researchers (including MBBS, MD and residents), faculty members, early-career investigators and independent researchers. Exceptional independent researchers were considered case by case. Applicants from under-resourced settings were especially encouraged to apply. The official page presented the program as global and remote and did not state a country-of-residence restriction.
The named project areas were broad but connected by an emphasis on research questions that computational tools could help address. They included target identification and prioritisation, drug repurposing, virtual screening and hit discovery, molecular dynamics, lead optimisation, ADMET and liability prediction, multi-omics, biomarker discovery, clinical bioinformatics, variant interpretation, transcriptomics, proteomics, companion diagnostics, liquid biopsy, assay design, biomedical knowledge graphs, trial design, feasibility and health economics. Interdisciplinary projects were welcomed.
A strong project under those terms would have been more specific than a general interest in artificial intelligence or biomedicine. It would identify a question, available or obtainable data, a computational approach, a way to evaluate the result and a realistic output over six months. A proposal combining computational prediction with an experimental question was a natural fit, especially for validation-award consideration, but Prognica encouraged proposals across its research capabilities. Prior experience with Prognica’s platform was not required; onboarding and training were included.
These are the eligibility terms published for the closed Class of 2026, not confirmed requirements for any later cohort. Applicants considering a future cycle should not assume that eligibility, research areas, geographic terms or selection criteria will remain the same. Check the new call when Prognica posts it.
How the application worked
For the closed round, applicants were directed to Prognica’s online application portal. The portal is no longer accepting submissions. Its published process started with submission of a proposal, CV and supporting materials, followed by an eligibility and completeness check, independent scientific review by two reviewers, a short interview for shortlisted candidates, final selection and offers followed by onboarding. The official page said the committee selected Fellows while reviewing cohort balance and diversity; validation awards were assigned at final selection.
The application information named a research proposal, a CV or academic record and supporting materials. It described applicants submitting a research plan and, when relevant, materials for consideration for the optional validation award. Applicants were also asked to agree to the program’s ethics, integrity and data-privacy guidelines. These are the materials and steps described for the 2026 round; the closed portal cannot be used to submit them now, and the list should not be treated as a checklist for a future call.
A useful proposal for the published program would have set out the research question, computational plan, data, feasibility, evaluation and expected output. A validation plan would identify the prediction to test, the proposed assay or experiment, its readout and practical requirements. For work involving human or clinical data, applicants needed to follow Prognica’s ethics, integrity and data-privacy requirements. The current official information reviewed here does not establish a new application form or document limits, so future applicants should follow the instructions in any new active portal.
Prognica listed [email protected] for program questions. The historical application page remains useful for understanding the previous process, but reaching that page does not reopen the application. Do not send an application or sensitive research material by email unless a future official call specifically instructs applicants to do so.
Published timeline and status
The official overview gave the following timeline for the inaugural cohort: applications opened on 1 August 2026 and closed on 30 August 2026. The application page explicitly says the portal stopped accepting submissions and late or incomplete applications are not carried forward. The review period was listed for 1–12 September 2026, with interviews on 15–23 September 2026. The application page said applicants would hear back by 26 September 2026 and listed that date for the selection announcement. The program timeline then scheduled onboarding and the six-month term to begin on 1 October 2026, with the program closing and cohort showcase on 31 March 2027.
The pages do not offer a route for late submission or indicate that applications remain open until a cohort fills. Accordingly, 30 August 2026 is retained as the genuine closing date, and the page is marked as a historical reference. The application page’s status text may lag behind its stated announcement date, so it should not be read as a current promise that results are still forthcoming. The separate Fellows directory is the official place currently presenting cohort members, but its displayed count of 15 does not match the application page’s stated selection of ten. This page leaves that difference visible for readers.
The only next-cycle guidance on the closed application page is that dates for the next cohort will be announced on the program page. No new deadline or opening date is published there. A future application period should be considered unannounced until Prognica posts a new call with its own dates and terms.
How the selection rubric was described
Prognica said each complete application was read by the program team and scored by two independent reviewers. The evaluation dimensions were research proposal quality, scientific merit, innovation potential, impact potential, research feasibility, validation readiness for the additional award, publication history relative to career stage, geographic diversity and disciplinary diversity. The published description used a five-point scale for criteria, with validation readiness relevant only to validation-award consideration. Aggregate scores were considered alongside cohort balance.
For an applicant, this rubric rewarded a proposal reviewers could assess. A clear question, evidence-based rationale, defined inputs, appropriate method, comparison or control, and practical schedule make scientific merit and feasibility easier to judge. It is also helpful to explain what result would count against the hypothesis. Negative or inconclusive findings can be informative if the plan says how they will be interpreted; claims of success without decision criteria are difficult to evaluate.
The validation award had a distinct readiness consideration. A computational result should lead to a testable experiment with a relevant readout, and the plan should address sample access, approvals, materials, assay scope and responsibility for the work. Since the program limited these awards to up to three Fellows, including a validation plan was not a requirement for general fellowship consideration. The published FAQ stated that applicants without a plan were not disadvantaged for the fellowship itself.
Interpreting the funding and benefits
The phrase “fully funded” on the program page referred to the fellowship benefits being provided without a fee. The same page described an estimated value for platform access and support, with an added laboratory-validation value for a small number of awardees. It did not promise a cash stipend, travel allowance, tuition payment or unrestricted research grant. Readers comparing this program with salaried fellowships or grants should use the detailed benefit description rather than infer cash support from the funding label.
The laboratory component was also described as work performed by Prognica’s team in its facility. The FAQ said recipients would not need to travel, although visits were welcome where practical. That matters for remote participation, but it does not mean every computational proposal receives laboratory work or that an award would support any experiment without review. The official description limited validation awards and said scope would be developed with the Fellow.
Frequently asked questions about the archived round
Can I apply to the 2026 cohort now?
No. Prognica says applications closed on 30 August 2026 and its portal is no longer accepting submissions. It also says late or incomplete applications are not carried forward.
Has Prognica announced a later cohort deadline?
No next-cohort date appears on the official program or application page reviewed for this archive. Prognica says future dates will be announced on the program page.
Was the fellowship a cash award?
The published $12,000 figure was an estimated value per Fellow for program benefits. The page does not describe it as cash paid to the Fellow. Up to three laboratory-validation awards were described with an indicative $8,000 value each.
Could an independent researcher apply?
Yes, independent researchers were listed, with exceptional independent researchers considered case by case. The previous call encouraged applicants from under-resourced settings and presented the program as global and remote.
Was a validation plan compulsory?
No. It was for consideration for the optional validation award. Prognica said applicants without such a plan remained eligible for the fellowship and were not disadvantaged for omitting it.
What should prospective applicants do?
Check the official program page for a new call. Use any future call’s application form, dates, eligibility language, benefit description and document instructions as controlling; the 2026 terms recorded here are historical.
Official links
- Prognica Research Fellows Program overview
- Prognica application page, now closed
- Prognica 2026 Fellows directory
The overview and application page are the primary sources for the closed call’s stated deadline, benefits, eligibility, process and future-cycle notice. The Fellows directory provides the published cohort listing and displays a count that differs from the application page’s stated selection number. Readers should consult Prognica directly for any newly announced cohort and should not rely on this archived cycle’s details as current application instructions.